- Home
- TRVI vs JYNT Comparison
TRVI vs JYNT Comparison
Compare TRVI & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- JYNT
- Stock Information
- Founded
- TRVI 2011
- JYNT 2010
- Country
- TRVI United States
- JYNT United States
- Employees
- TRVI N/A
- JYNT N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- JYNT Multi-Sector Companies
- Sector
- TRVI Health Care
- JYNT Miscellaneous
- Exchange
- TRVI Nasdaq
- JYNT Nasdaq
- Market Cap
- TRVI 211.4M
- JYNT 179.2M
- IPO Year
- TRVI 2019
- JYNT 2014
- Fundamental
- Price
- TRVI $2.75
- JYNT $11.06
- Analyst Decision
- TRVI Strong Buy
- JYNT Strong Buy
- Analyst Count
- TRVI 8
- JYNT 2
- Target Price
- TRVI $9.13
- JYNT $17.50
- AVG Volume (30 Days)
- TRVI 659.5K
- JYNT 43.7K
- Earning Date
- TRVI 11-06-2024
- JYNT 11-07-2024
- Dividend Yield
- TRVI N/A
- JYNT N/A
- EPS Growth
- TRVI N/A
- JYNT N/A
- EPS
- TRVI N/A
- JYNT N/A
- Revenue
- TRVI N/A
- JYNT $120,795,620.00
- Revenue This Year
- TRVI N/A
- JYNT $0.70
- Revenue Next Year
- TRVI N/A
- JYNT N/A
- P/E Ratio
- TRVI N/A
- JYNT N/A
- Revenue Growth
- TRVI N/A
- JYNT 5.26
- 52 Week Low
- TRVI $0.97
- JYNT $8.30
- 52 Week High
- TRVI $4.00
- JYNT $17.82
- Technical
- Relative Strength Index (RSI)
- TRVI 37.52
- JYNT 45.09
- Support Level
- TRVI $2.80
- JYNT $11.05
- Resistance Level
- TRVI $3.22
- JYNT $12.70
- Average True Range (ATR)
- TRVI 0.20
- JYNT 0.43
- MACD
- TRVI -0.03
- JYNT -0.03
- Stochastic Oscillator
- TRVI 14.68
- JYNT 6.29
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.